Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CeriBellCBLL +9.17%12 Days Sales Outstanding is 51.49 as of Jun. 2026, which is 3% below its 10-year median of 53.31. GuruFocus rates CBLL with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 812 Medical Devices & Instruments companies, CeriBell ranks better than 69.09% on this metric.
CeriBell's average Accounts Receivable for the
three
months ended in Jun. 2026 was $15.9 Mil. CeriBell's Revenue for the
three
months ended in Jun. 2026 was $28.1 Mil.
Hence, CeriBell's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 51.49.
The historical rank and industry rank for CeriBell's Days Sales Outstanding or its related term are showing as below:
CBLL'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 51.15 Med: 53.31 Max: 74.56
Current: 51.15
During the past 4 years, CeriBell's highest Days Sales Outstanding was 74.56. The lowest was 51.15. And the median was 53.31.
CBLL's Days Sales Outstanding is ranked better than 69.09% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: 65.165
vs CBLL: 51.15
CeriBell's Days Sales Outstanding
increased
from Jun. 2025 (50.82) to Jun. 2026 (51.49).
CeriBell (NAS:CBLL) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
CeriBell Days Sales Outstanding Related Terms
CeriBell Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for CeriBell's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CBLL vs TCMD, CERS, SSII: Days Sales Outstanding Comparison
For the Medical Devices subindustry, CeriBell's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CeriBell Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CeriBell's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where CeriBell's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CeriBell (CBLL) has a Days Sales Outstanding of 51.49 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on CeriBell and its competitors. This is near median its historical median of 53.31. Over the past decade, CeriBell's Days Sales Outstanding has ranged from 51.15 to 74.56. According to the industry distribution chart, CeriBell ranks #251 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 30.9%.
Is CeriBell's Days Sales Outstanding too high?
CeriBell's current Days Sales Outstanding of 51.49 is near median its 10-year median of 53.31. Over the past 10 years, this metric has ranged from a low of 51.15 to a high of 74.56. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.17. CeriBell's value of 51.49 is 21% below this industry median. Based on the distribution chart, CeriBell ranks #251 out of 812 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, CeriBell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CeriBell's Days Sales Outstanding compare to TCMD and CERS?
According to the Medical Devices & Instruments industry distribution chart, CeriBell ranks #251 out of 812 companies for Days Sales Outstanding. This puts CeriBell in the upper half of its industry. The industry median Days Sales Outstanding is 65.17. CeriBell's value of 51.49 is 21% below this benchmark. Historically, CeriBell's own Days Sales Outstanding has ranged from 51.15 to 74.56 over the past decade. While the company's 10-year median is 53.31 vs. the industry median of 65.17, CeriBell has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.17, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CeriBell's current Days Sales Outstanding of 51.49 is 21% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on CeriBell and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CeriBell's current Days Sales Outstanding is 51.49, which is near median its own 10-year median of 53.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CeriBell stock overvalued right now?
CeriBell (CBLL) has a current Days Sales Outstanding of 51.49. The current Days Sales Outstanding is 51.49, which is near median its 10-year median of 53.31 and 21% below the Medical Devices & Instruments industry median of 65.17. CeriBell's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For CeriBell (CBLL), the current Days Sales Outstanding is 51.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.
12GF Score
Get the complete analysis for CBLL
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBLL has been successfully added to your 
